

Review Article

Neurological and Neurobehavioral Disorders Associated with *Toxoplasma gondii* Infection in Humans

Maxwell A. Virus , Evie G. Ehrhorn , LeeAnna M. Lui , and Paul H. Davis 

Department of Biology, University of Nebraska at Omaha, Omaha, Nebraska, USA

Correspondence should be addressed to Maxwell A. Virus; maxwellanthony11@gmail.com

Received 2 December 2020; Accepted 15 September 2021; Published 19 October 2021

Academic Editor: Hassen Mamo

Copyright © 2021 Maxwell A. Virus et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The intracellular parasite *Toxoplasma gondii* is estimated to infect up to 30% of the world population, leading to lifelong chronic infection of the brain and muscle tissue. Although most latent *T. gondii* infections in humans have traditionally been considered asymptomatic, studies in rodents suggest phenotypic neurological changes are possible. Consequently, several studies have examined the link between *T. gondii* infection and diseases such as schizophrenia, epilepsy, depression, bipolar disorder, dysphoria, Alzheimer's disease, Parkinson's disease, and obsessive-compulsive disorder (OCD). To date, there is varying evidence of the relationship of *T. gondii* to these human neurological or neurobehavioral disorders. A thorough review of *T. gondii* literature was conducted to highlight and summarize current findings. We found that schizophrenia was most frequently linked to *T. gondii* infection, while sleep disruption showed no linkage to *T. gondii* infection, and other conditions having mixed support for a link to *T. gondii*. However, infection as a cause of human neurobehavioral disease has yet to be firmly established.

1. *Toxoplasma gondii* Infection

Toxoplasma gondii is an intracellular protozoan parasite estimated to infect up to one-third of the world population [1]. The parasitic life cycle is complex, involving cats as the definitive host and virtually all other mammals and birds as intermediate hosts [2]. Humans may become infected by eating undercooked meat from an infected host or ingesting oocysts shed in infected cat feces. The oocysts are environmentally resistant and can be infective for lengthy periods [3]. Although uncommon, drinking water has also been a source of infection [4, 5]. Finally, transplacental transmission is a concerning route of infection, transmitted from a mother's primary infection to the developing fetus, often leading to infection-related birth defects [6].

Upon infection, the initial acute stage of infection is effectively controlled in healthy hosts, forcing the parasite to differentiate into a chronic intracellular tissue cyst stage [7]. Intracellular tissue cyst formation takes place in a variety of tissues that include skeletal muscles, the heart, and the brain, with the brain housing a majority of the tissue cyst

load in both murine and human models [7–9]. This chronic (or latent) stage of infection, consisting of the bradyzoite parasite stage, is not eliminated via host immune response or even long-term chemotherapeutic options [10].

Although chronic infection has been considered largely asymptomatic in immunocompetent humans, chronic *T. gondii* infection has been shown to produce alterations in rodent behavior [11]. Numerous studies have begun to question whether alteration in behavior is limited to rodents, with the possibility that *T. gondii* infection may affect or instigate behavior or neurological disease state in humans. For example, a recent review by Martinez et al. documented 8 studies relating *T. gondii* to personality changes including aggression, disregard for rules, and self-directed violence [12]. Researchers aptly noted the limitations in measuring human behavior, including complex relationships between the brain, genetics, and social environments; differences in tests used for diagnosing infection and neurobehavioral and neurologic disorders [11]; and difficulty in establishing causal relationships between infection and neurologic disease. Even with the limitations in the studies, the work

reinforces the hypothesis that *T. gondii* may have a measurable effect on the human central nervous system.

This present review evaluates current proposed neurobehavioral and neurological disorders associated with *T. gondii* infection and includes schizophrenia [13–15], obsessive-compulsive disorder [16], epilepsy [17, 18], depression [19], bipolar type I disorder [20], dysphoria [21], Alzheimer's [22], and Parkinson's [23]. A review of *T. gondii* literature and its possible relation with neurobehavioral disorders was conducted and organized into Table 1. Where investigated, potential differences between pre- and postnatal infection outcomes are described.

2. Mice and Rats as a Host for *Toxoplasma gondii*

Mice and rats are widely used laboratory hosts for *T. gondii* and have been studied extensively as model organisms for infection. Some have gathered evidence that chronic rodent *T. gondii* infection is associated with impaired motor performance, deficits in spatial learning and memory, reduced anxiety, higher activity levels in both novel and familiar environments, sensory attention deficits, altered novelty seeking behavior, and longer reaction times [24–28].

A most interesting reported change in rodents is the reduced avoidance of feline predators and potential attraction to cat urine, with pheromones in the cat urine seeming to generate a signal similar to sexual attraction, thus perpetuating the parasite's sexual lifecycle [11, 29]. The mechanism for this effect is not firmly established, but it is conceivable that nonrandom distribution of and/or activity from the parasite within certain brain regions may contribute to altered behavioral responses. *T. gondii* cysts have been shown to infect up to 92% of brain regions in mice [30], and the selective hypercolonization of various brain regions has been implicated in this modulation of defensive and aversive behaviors in rodents [11, 30, 31]. Some studies suggest that certain brain regions are consistently more infected than others, with tissue cyst density up to twelve times higher [32]. These include the amygdala (responsible for fear responses) and the nucleus accumbens which contains bundles of dopaminergic neurons and is responsible for brain stimulation reward [29, 32, 33]. Areas with consistently low numbers of tissue cysts were reported in the cerebellum, the pontine nuclei, the caudate putamen, the accessory olfactory bulb, and virtually all compact masses of myelinated axons [30, 32, 34, 35]. These studies suggest that nonrandom parasite distribution in the brain may be associated with observed changes within infected animals [36].

Congenital transmission of *T. gondii* in rodents has been considered to have a potential relationship with behavioral disorders, in addition to changes in learning and memory [37–41]. However, definitive findings have not been produced from studies to date. More work is needed in order to link congenital *T. gondii* infection in rodent models to cognitive disorders.

3. Humans as a Host for *Toxoplasma gondii*

Due to the inability to clear chronic infection once established, easily controlled human pre-/postinfection studies are not ethically feasible, thus making studies of causal relationships less likely. Similarly, it is difficult to establish whether chronically infected adults were infected congenitally or after birth, complicating retrospective studies investigating maternal-fetal transmission effects. *T. gondii* CNS tissue cyst localization in humans is also less well studied, with the data available primarily originating from autopsies of AIDS patients [42]. AIDS patients often have rampant toxoplasmic infections, which cause extensive pathologic lesions to occur throughout the brain. Lesions observed in humans had an apparent stochastic localization, which suggests stochastic localization of the initial parasite tissue cyst [43]. In rodents, tissue cyst localization has been hypothesized to occur more often in the amygdalar brain region due to the modulated fear responses; however, this localization is not apparent in humans [29]. Thus, differences in potential effects between the murine and human host could be due to the overall relatively lower density of parasites in the human brain [44, 45].

4. Possible Neurochemistry and Pathway Effects

Many of the neurobehavioral and neurological symptoms that are postulated to be associated with *T. gondii* infection can be correlated to the potential modulation of dopamine in the host brain. *T. gondii* chronic infection is reported to raise whole brain dopamine levels in mice by up to 15% [46]. Hypotheses about the source of the increase in dopamine neurotransmitters include the inflammatory-mediated release of dopamine following cytokine secretion such as interleukin-2 [47] and the existence and activity of tyrosine hydroxylase enzymes in the *T. gondii* genome [48, 49]. It was previously proposed that these tyrosine hydroxylase parasitic genes (AAH1 and AAH2), which encode proteins that produce L-DOPA, interfere with dopamine synaptic transmission and that this interference may lead to neurologic changes [50]. However, a recent AAH2 gene deletion study showed that the enzyme was not required for neurobehavioral changes seen with *T. gondii* murine infection and suggested that effects related to chronic *T. gondii* infection are more likely mediated by neuroinflammation [50]. Variability in immune responses and/or secreted parasite kinases which effect host cell signaling are also potential causes of the observed effects [51]. In addition to potential modulation of dopamine, *T. gondii* infection reportedly affects other neurotransmitter systems such as GABA [52], serotonin [53], noradrenaline [53], nitric oxide [54, 55], kynurenic acid (KYNA) [56], glutamate [57], and the level of proinflammatory cytokines [58]. It is also known that *T. gondii* infection shares transcriptional pathways which overlap other CNS disease states [59]. Taken together, there are a number of possible pathways potentially disrupted by parasite infection which can account for observed differences in model organism and potentially in humans.

TABLE 1: Studies conducted examining possible linkages of *T. gondii* infection with neurobehavioral symptoms and disorders.

Disease	Reference	# of subjects	Mean age (yr)	Linkage	Finding
Alzheimer's	Kusbeci et al. [22]	71	68 ± 16	+	<i>T. gondii</i> seropositivity seen to be associated with Alzheimer's
	Mahami-Oskouei et al. [76]	150	76 ± 7.2	-	<i>T. gondii</i> seropositivity not seen to be associated with Alzheimer's
	Perry et al. [72]	219	80 ± 7.2	-	<i>T. gondii</i> seropositivity not seen to be associated with Alzheimer's
	Bouscaren et al. [73]	1662	73 ± 7.0	-	<i>T. gondii</i> seropositivity not seen to be associated with Alzheimer's
	Cong et al. [74]	88	16 – 91	-	<i>T. gondii</i> seropositivity not seen to be associated with Alzheimer's
	Menati Rashno et al. [77]	87	62 ± 21	-	<i>T. gondii</i> seropositivity not seen to be associated with Alzheimer's
	Menati Rashno et al. [77]	174	21 ± 69	-	<i>T. gondii</i> seropositivity not seen to be associated with Alzheimer's
Bipolar disorder	Pearce et al. [85]	7440 (M)	15 – 39	+	<i>T. gondii</i> seropositivity seen to be associated with bipolar disorder I
	Hamdani et al. [86]	216	47 ± 11	+	<i>T. gondii</i> seropositivity significantly different between groups (3.6x increased likelihood)
	Fond et al. [99]	266	44 ± 13	+	<i>T. gondii</i> seropositivity seen to be associated with more bipolar disorder depressive episodes
	Del Grande et al. [83]	101	≥40	+	<i>T. gondii</i> seropositivity seen to be associated with bipolar disorder
	Alvarado-Esquivel et al. [87]	462	40 ± 14	+	<i>T. gondii</i> seropositivity seen to be associated with a specific type of bipolar disorder
	Affi et al. [82]	40	32 ± 8	+	<i>T. gondii</i> seropositivity and serointensity seen to be associated with bipolar disorder and oxidative stress
	Hamdani et al. [84]	334	18 – 65	+	<i>T. gondii</i> seropositivity seen to be associated with bipolar disorder
	Frye et al. [88]	52	-	+	<i>T. gondii</i> seropositivity seen to be associated with bipolar disorder
	Hamdani et al. [89]	78	42	+	<i>T. gondii</i> seropositivity seen to be associated with bipolar disorder
	Oliveira et al. [90]	305	41 ± 14	+	<i>T. gondii</i> seropositivity seen to be associated with bipolar disorder
	Stich et al. [92]	46	-	-	<i>T. gondii</i> seropositivity not seen to be associated with bipolar disorder
	Del Grande et al. [95]	7440	15 – 39	-	<i>T. gondii</i> seropositivity not seen to be associated with bipolar disorder
	Chaudhury and Ramana [93]	216	-	+	<i>T. gondii</i> maternal seropositivity seen to be associated with bipolar disorder in offspring
Mortensen et al. [91]	127	27	-	<i>T. gondii</i> maternal seropositivity not seen to be associated with bipolar disorder in offspring	
Freedman et al. [94]	214	Maternal: 27.7 Paternal: 32.2	-	<i>T. gondii</i> maternal seropositivity not seen to be associated with bipolar disorder in offspring	

TABLE 1: Continued.

Disease	Reference	# of subjects	Mean age (yr)	Linkage	Finding
Depression/ dysphoria/ hopelessness	Alvarado-Esquivel et al. [101]	445	38 ± 13	+	<i>T. gondii</i> seropositivity seen to be associated with depression
	Duffy et al. [102]	70	47 ± 10	+	<i>T. gondii</i> seropositivity seen to be associated with depression and dysphoria
	Yalin et al. [103]	37	11 – 18	+	<i>T. gondii</i> seropositivity seen to be associated with depression
	Nasirpour et al. [103]	174	62 ± 22	+	<i>T. gondii</i> seropositivity seen to be associated with depression
	Groër et al. [105]	414	–	+	<i>T. gondii</i> seropositivity seen to be associated with depression
	Alvarado-Esquivel et al. [109]	400	23 ± 18	-	<i>T. gondii</i> seropositivity not seen to be associated with depression in pregnant women
	Gale et al. [108]	1846	29 ± 0.4	-	<i>T. gondii</i> seropositivity not seen to be associated with major depressive disorder
	Flegr and Hodný [110]	5535	32 ± 13	-	<i>T. gondii</i> seropositivity not seen to be associated with depression
	Wadhawan et al. [21]	306	46 ± 16	-	<i>T. gondii</i> seropositivity not seen to be associated with dysphoria and hopelessness
	Pearce et al. [20]	7440 (M)	15 – 39	-	<i>T. gondii</i> seropositivity not seen to be associated with unipolar mood disorders such as depression
	Cong et al. [74]	78	16 – 91	-	<i>T. gondii</i> seropositivity not seen to be associated with depression
	Zaki et al. [111]	168	35 ± 9	-	<i>T. gondii</i> seropositivity not seen to be associated with depression
	Nourollahpour Shiadeh et al. [112]	360	28 ± 5	-	<i>T. gondii</i> seropositivity not seen to be associated with depression
Shahnaz et al. [186]	180	–	-	<i>T. gondii</i> seropositivity not seen to be associated with depression	
Abd El-Aal et al. [114]	178	36 ± 14	-	<i>T. gondii</i> seropositivity not seen to be associated with depression	
Epilepsy	Ngoungou et al. [17]	2888 (M)	All ages	+	<i>T. gondii</i> seropositivity seen to be an epilepsy risk factor
	Palmer [18]	204 (M)	No ages listed	+	<i>T. gondii</i> seropositivity seen to be associated with epilepsy, especially cryptogenic epilepsy
	Stommel et al. [119]	45	43	+	<i>T. gondii</i> seropositivity seen to be associated with cryptogenic epilepsy
	Ngô et al. [59]	149	–	+	<i>T. gondii</i> seropositivity seen to be significantly higher in epilepsy patients
	Abd El-Aal et al. [114]	178	36 ± 14	+	<i>T. gondii</i> seropositivity seen to be associated with epilepsy
	Eltantawy et al. [128]	192	9 ± 4	+	<i>T. gondii</i> seropositivity seen to be associated with cryptogenic epilepsy
	Allahdin et al. [129]	185	2 – 39	+	<i>T. gondii</i> seropositivity seen to be associated with epilepsy
	Eraky et al. [130]	90	5 ± 3	+	<i>T. gondii</i> seropositivity seen to be associated with cryptogenic epilepsy
Zibaei et al. [131]	170	–	+	<i>T. gondii</i> seropositivity seen to be associated with epilepsy	

TABLE 1: Continued.

Disease	Reference	# of subjects	Mean age (yr)	Linkage	Finding
	Yazar et al. [132]	150	36 ± 15	+	<i>T. gondii</i> seropositivity seen to be associated with epilepsy
	Cong et al. [74]	104	16 – 91	-	<i>T. gondii</i> seropositivity not seen to be associated with epilepsy
	Babaie et al. [118]	627	33 ± 10	-	<i>T. gondii</i> seropositivity not seen to be associated with epilepsy
	Alvarado-Esquivel et al. [125]	198	39 ± 16	-	<i>T. gondii</i> seropositivity not seen to increase the risk of certain types of epilepsy
	Akyol et al. [117]	150	28 ± 3.2	-	<i>T. gondii</i> seropositivity not seen to be associated with epilepsy
	Miman et al. [116]	55	7 – 16	-	<i>T. gondii</i> seropositivity not seen to be associated with epilepsy
Headaches	Koseoglu et al. [134]	104	33 ± 10	+	<i>T. gondii</i> seropositivity seen to be associated with migraines
	Flegr and Escudero [137]	1266	34 ± 12	+	<i>T. gondii</i> seropositivity seen to be associated with migraines
	Jouyani et al. [138]	100	20 – 60	+	<i>T. gondii</i> seropositivity seen to be associated with migraines
	Prandota [133]	108	10 – 66	-	<i>T. gondii</i> seropositivity not seen to be associated with migraines
	Alvarado-Esquivel et al. [136]	210	42 ± 15	-	<i>T. gondii</i> seropositivity not seen to be associated with headaches, but high serointensity seen to be associated with recurring headaches
OCD	Flegr and Horáček [140]	7471	32 – 35 ± 12	+	<i>T. gondii</i> seropositivity seen to be associated with OCD
	Miman et al. [16]	142	34 ± 12	+	<i>T. gondii</i> seropositivity seen to be significantly higher in OCD patients (48%) than controls (19%)
	Nayeri Chegeni et al. [143]	9873 (M)	All ages	+	<i>T. gondii</i> seropositivity seen to be associated with OCD
	Akaltun et al. [141]	60	Children and adolescents	+	<i>T. gondii</i> seropositivity seen to be associated with increased risk of OCD in children and adolescents
	Çakın Memik et al. [142]	87	12 ± 3	-	<i>T. gondii</i> seropositivity not seen to be associated with OCD
	Cong et al. [74]	82	16 – 91	-	<i>T. gondii</i> seropositivity not seen to be associated with OCD
	Zaki et al. [111]	179	35 ± 9	-	<i>T. gondii</i> seropositivity not seen to be associated with OCD
	Flegr and Escudero [137]	1256	34 ± 12	-	<i>T. gondii</i> seropositivity not seen to be associated with OCD
Sleep	Ahmad et al. [151]	2031	44 ± 17	-	<i>T. gondii</i> seropositivity not seen to be associated with sleep disturbances
	Corona et al. [153]	833	44.3 ± 17	-	<i>T. gondii</i> seropositivity not seen to be associated with sleep disturbances
	Dard et al. [152]	170	53 (median age)	-	<i>T. gondii</i> seropositivity not seen to be associated with sleep disturbances

TABLE 1: Continued.

Disease	Reference	# of subjects	Mean age (yr)	Linkage	Finding
Suicide	Okusaga et al. [49]	950	38 ± 11	+	<i>T. gondii</i> seropositivity seen to be associated with past suicidal behavior in young schizophrenic patients
	Yagmur et al. [154]	400	24 ± 7	+	<i>T. gondii</i> seropositivity seen to be associated with suicide
	Ling et al. [155]	WHO Europe*	All ages	+	<i>T. gondii</i> seropositivity seen to be associated with suicide in women of postmenopausal age
	Bak et al. [156]	290	43 ± 16	+	<i>T. gondii</i> seropositivity seen to be associated with suicide attempts
	Coryell et al. [158]	222	35 ± 14	+	<i>T. gondii</i> seropositivity seen to be associated with suicide attempts
	Dickerson et al. [159]	72	40 ± 10	+	<i>T. gondii</i> seropositivity seen to be associated with suicide attempts
	Ansari-Lari et al. [160]	99	—	+	<i>T. gondii</i> seropositivity seen to be associated with suicide attempts
	Arling et al. [161]	257	40 ± 9.8	-	<i>T. gondii</i> seropositivity not seen to be associated with suicide
	Alvarado-Esquivel et al. [162]	156	34 ± 10	-	<i>T. gondii</i> seropositivity not seen to be associated with suicide attempts
	Sari and Kara [157]	100	16	-	<i>T. gondii</i> seropositivity not seen to be associated with suicide attempts
Sugden et al. [202]	837	38	-	<i>T. gondii</i> seropositivity not seen to be associated with suicide attempts	
Parkinson's disease	Miman et al. [23]	92	66 ± 12	+	<i>T. gondii</i> seropositivity seen to be associated with Parkinson's disease
	Ramezani et al.	150	63 ± 6	+	<i>T. gondii</i> seropositivity seen to be associated with Parkinson's disease
	Mahami-Oskouei et al. [163]	150	63 ± 11	-	<i>T. gondii</i> seropositivity not seen to be associated with Parkinson's disease
	Zhou et al. [164]	1086 (M)	62 ± 76	-	<i>T. gondii</i> seropositivity not seen to be associated with Parkinson's disease
	Celik et al. [48]	100	63 ± 12	-	<i>T. gondii</i> seropositivity not seen to be associated with Parkinson's disease
	Fallahi et al. [165]	230	75 ± 14	-	<i>T. gondii</i> seropositivity not seen to be associated with Parkinson's disease
	Alvarado-Esquivel et al. [203]	260	38 – 95	-	<i>T. gondii</i> seropositivity not seen to be associated with Parkinson's disease
	Gendy et al. [166]	90	53	-	<i>T. gondii</i> seropositivity not seen to be associated with Parkinson's disease
Schizophrenia	Torrey and Yolken [167]	(M)	-	+	<i>T. gondii</i> seropositivity seen to be associated with schizophrenia
	Leweke et al. [14]	148	30 ± 10	+	<i>T. gondii</i> seropositivity seen to be associated with recent onset schizophrenia
	Cetinkaya et al. [15]	200	37 ± 11	+	<i>T. gondii</i> seropositivity seen to be associated with schizophrenia
	Alipour et al. [179]	124	37 ± 10	+	<i>T. gondii</i> seropositivity seen to be associated with schizophrenia
	Muflikhah et al. [178]	94	-	+	<i>T. gondii</i> seropositivity seen to be associated with schizophrenia

TABLE 1: Continued.

Disease	Reference	# of subjects	Mean age (yr)	Linkage	Finding
	Burgdorf et al. [177]	81912	18 – 67	+	<i>T. gondii</i> seropositivity seen to be associated with schizophrenia
	Kezai et al. [180]	140	39 ± 9	+	<i>T. gondii</i> seropositivity seen to be associated with schizophrenia
	Fond et al. [181]	250	32 ± 8.6	+	<i>T. gondii</i> seropositivity seen to be associated with schizophrenia
	Cong et al. [74]	89	16 – 91	+	<i>T. gondii</i> seropositivity seen to be associated with schizophrenia
	Alvarado-Esquivel et al. [204]	218	43 ± 17	+	<i>T. gondii</i> seropositivity seen to be associated with schizophrenia
	Zaki et al. [111]	214	35 ± 9	+	<i>T. gondii</i> seropositivity seen to be associated with schizophrenia
	Ansari-Lari et al. [160]	251	18 – 59	+	<i>T. gondii</i> seropositivity seen to be associated with schizophrenia
	Wang et al. [205]	800	22 ± 5	+	<i>T. gondii</i> seropositivity seen to be associated with schizophrenia
	Khademvatan et al. [186]	100	36 ± 10	+	<i>T. gondii</i> seropositivity seen to be associated with schizophrenia, higher prevalence in females than males
	Flegr et al. [184]	173	35 ± 8	+	<i>T. gondii</i> seropositivity seen to be associated with schizophrenia, higher prevalence in males than females
	Al-Hussainy et al. [185]	177	–	+	<i>T. gondii</i> seropositivity seen to be associated with schizophrenia, higher prevalence in males than females
	Karabulut et al. [183]	145	41 ± 12	-	<i>T. gondii</i> seropositivity not seen to be associated with schizophrenia
	Xiao et al. [190]	837	–	+	<i>T. gondii</i> maternal seropositivity seen to be associated with schizophrenia in offspring
	Mortensen et al. [191]	1366	–	+	<i>T. gondii</i> maternal seropositivity seen to be associated with schizophrenia in offspring
	Brown [189]	186	25 ± 5	-	<i>T. gondii</i> maternal seropositivity not seen to be associated with schizophrenia in offspring

A linkage "+" indicates a statistically significant association with *T. gondii* as determined by the original authors, whereas a "-" indicates that the association does not meet their statistical threshold. * represents data from the European Mortality Database and varies in countries and years. POMS: profile of mood states. (M): meta-analysis.

Studying *T. gondii* infection and its effects on neurochemistry in humans is more challenging. Yet, human behavioral studies have provided insight to the effects of infection on attributes such as reaction time, masculinity, and personality traits. Humans with *T. gondii* infection appear to have slower reaction times than humans without *T. gondii* infection [60] and also have a higher amount of observed traffic accidents and work accidents, which has been cataloged in four retrospective studies [61–64]. Testosterone levels are higher in college-aged men infected with *T. gondii* [65] and photos of the infected men were rated by females as more masculine [66]. In contrast, female students with *T. gondii* infection had decreased

levels of testosterone [65]. Furthermore, men infected with *T. gondii* demonstrated personality traits such as more willingness to disregard rules and to be more suspicious and jealous, whereas infected women tended to be more warm-hearted, outgoing, and easy-going [26]. Both men and women who were infected indicated a decrease in novelty seeking behavior and conscientiousness, but were more entrepreneurial [67–70].

Although infection with *T. gondii* was previously considered asymptomatic, there are clear suggestions of phenotypic CNS alterations due to chronic *T. gondii* infection. To study how far-reaching these effects could be, research continues to attempt to correlate *T. gondii* infection with changes in

behavior and manifestations of neurobehavioral or neurological disorders. Table 1 lists published studies evaluating the CNS disorder associations.

5. Detecting *Toxoplasma gondii*

The diagnosis of *T. gondii* infection has traditionally been made by performing serological tests for the presence of antibodies produced by the host immune system in response to an exposure. Cerebrospinal fluid (CSF) can also be drawn and used to detect the *T. gondii* antibodies although this technique is more difficult and expensive. Most studies listed in Table 1 used an enzyme-linked immunosorbent assay (ELISA) and seropositivity of *T. gondii*-IgG antibodies to detect whether subjects had been exposed to the parasite. Serointensity, or the relative concentration of IgG antibodies present in serological readings, was also measured in some studies, although the importance of differences in serointensity or the causes of these differences have not been established. Notably, these methods do not permit the ability to distinguish maternal transmission from postnatal acquisition if evaluated several weeks or more after birth.

Overall, the categorized studies reviewed in Table 1 suggest potential correlations between *T. gondii* infection and some neurobehavioral or neurologic disorders. Each of the evaluated disease categories that were evaluated are discussed below.

6. Methodology and Results

The methodology utilized to find research articles to document current potential neurobehavioral disorders associated with chronic infection of *T. gondii* included utilizing specific terms in PubMed. These terms include “*T. gondii* neurobehavioral disorders,” “*T. gondii* neurologic disorders,” and “Effects of chronic toxoplasmosis” limited to the year 1990 to present. Cited sources from these papers were also used as resources for finding related studies. If studies included differentiation between maternal-fetal transmission and postfetal acquisition, these were noted.

6.1. Alzheimer’s Disease. Kusbeci et al. found that *T. gondii* seropositivity was significantly higher in 34 Alzheimer’s patients compared to 37 control patients ($p = 0.005$) [22]; however, the Alzheimer’s population was substantially older (68.1 vs. 62.9 years). Prandota suggests that Alzheimer’s may be associated with congenital transmission; however, there was no significant correlation between them [71]. More recent studies with larger populations did not detect correlations or statistical significance between Alzheimer’s and *T. gondii* infection [72–78]. Thus, it is undetermined if Alzheimer’s disease and *T. gondii* infection are linked. Notably, however, *T. gondii* exposure may be associated with cognitive decline in older persons [79, 80]. Studies in murine models have shown an inconsistency between the linkages between Alzheimer disease progression and *T. gondii*. Both Torres et al. and Mahmoudvand et al. found that *T. gondii* infection induced or worsened pathological progression and signs associated with Alzheimer’s disease [28, 75]. How-

ever, Jung et al. suggested otherwise, stating that *T. gondii* infection suppressed the neurodegenerative-associated pathogenesis in an Alzheimer’s disease murine model [81]. Therefore, future studies must be done to determine whether an association between *T. gondii* infection and cognition changes due to Alzheimer’s disease exists.

6.2. Bipolar Disorder. It has been contemplated that latent *T. gondii* may trigger CNS oxidative stress, leading to immune-inflammatory processes that could promote or resemble CNS changes seen in bipolar disorder [82–84]. In studies conducted by Pearce et al. and Hamdani et al, it was found that patients seropositive for *T. gondii* infection were approximately 2.3- and 2.7-folds more likely to have a history of bipolar disorder type I with manic and depressive symptoms than respondents who tested negative for the *T. gondii* antibody [85, 86]. A more recent 2019 study also found a possible linkage between depressive bipolar disorder and *T. gondii* seropositivity ($p = 0.04$) [87]. While Stich et al. found no significant association between bipolar disorder and *T. gondii*, a multitude of studies suggest otherwise [88–92]. Further, studies of maternal-specific transmission of *T. gondii* infection have not found significant association with bipolar disorder [91, 93–95].

The CNS-acting drugs haloperidol, cyamemazine, loxapine, zuclopenthixol, and fluphenazine (but not valproate) showed at least moderate antitoxoplasmic activity when evaluated *in vitro* [96, 97]. *T. gondii*-seropositive patients with bipolar disorder I who were treated with valproate, haloperidol, zuclopenthixol, cyamemazine, and/or loxapine experienced on average two fewer lifetime depressive episodes than those who were treated with medications with lower *in vitro* anti-*T. gondii* activity [98, 99]. However, none of these drugs have been shown to affect the latent tissue cyst stage of the parasite. While it is conceivable that *T. gondii*-positive patients may derive enhanced benefit from receiving medications that have shown anti-*T. gondii* activity, it is notable that standard antiparasitic treatment options have not shown marked improvement in patient psychopathology [100]. Taken together, the available studies evaluating *T. gondii* infection associated with some form of bipolar disorder (Table 1) suggests a linkage more often than not.

6.3. Depression, Dysphoria, and Hopelessness. Studies have been inconsistent in linking *T. gondii* infection with depression, with a majority of studies finding that *T. gondii* and depression are not linked. Alvarado-Esquivel et al. suggested a linkage between depression and *T. gondii*, especially in younger populations ages 17-30 years old [101], but this study was limited in geography. Duffy et al. also found a potential correlation between chronic *T. gondii* infection and depression in women veterans indicating a higher depression score [102]. Wadhawan et al. found that the relationship between *T. gondii* IgG seropositivity and ethnicity was statistically significant with regard to the Hispanic population. This could point to a previously unknown relationship between *T. gondii* and those of Hispanic origin [21]. In a study presented by Yalın Sapmaz et al., there was also a suggested relationship between young adolescents,

depression, and *T. gondii* seropositivity [103]. This association is also seen in a few other studies as well [104, 105]. However, in a study conducted by Mahmoud et al., depression was correlated to reactivated *T. gondii* and not chronic infection of *T. gondii* in BALB/c mice [106]. In a study conducted in 2020, a similar result was found where chronic infection of *T. gondii* did not appear to have correlation with depression, yet there was a correlation with the acute stage [107]. Multiple other studies found no association between latent *T. gondii* and depression [74, 108–114]. Flegr and Hodný postulate that a pathogen responsible for mood disorder may not be *T. gondii* but rather a different feline-borne pathogen [110]. Presently, a link between depression and *T. gondii* infection cannot be determined until further studies are completed.

6.4. Epilepsy. Tachyzoite infection of neurons has shown to deregulate calcium influx upon stimulation with glutamate [115], and calcium is known to play an important role in the initiation and spread of seizure activity. Two meta-analysis studies suggest a positive correlation between *T. gondii* infection and development of epilepsy [17, 18], whereas other studies evaluated the potential relationship between epilepsy and *T. gondii* but found no statistical significance [74, 116–118]. Stommel et al. found a possible association with cryptogenic epilepsy and chronic *T. gondii* infection [119]. In addition, it was reported that rats with chronic and acute *T. gondii* infection had a lower seizure threshold compared to uninfected healthy rats, and the average seizure threshold was restored only once a pharmacological blockade of dopaminergic receptors occurred [120]. Given the results of these studies, it is conceivable that the effects of chronic *T. gondii* infection on dopamine concentrations and/or acute *T. gondii* infection on calcium concentrations may increase the risk of seizures and epilepsy.

Infection by *T. gondii* has also been associated with changes in sex hormone levels, such as increased testosterone serum concentrations [121–123]. Testosterone concentration is known to affect dopamine signaling pathways, changing the sensitivity of the nigrostriatal pathway to dopamine [124]. This may suggest that *T. gondii* may be correlated to specific types of epilepsy, such as hormone-driven epilepsy [125]. One hormone-related epilepsy, catamenial epilepsy, may be influenced by *T. gondii* infection due to modified dopamine levels, which are linked to the level of estrogen [126]. There is a reported strong correlation ($p < 0.001$) between the prevalence of epilepsy and seropositivity of toxoplasmosis in pregnant women [18]. Further, a case study reports a patient with congenital toxoplasmosis and temporal lobe epilepsy, suggesting a relationship between the two [127]. Altogether, multiple studies point towards the idea that epilepsy is linked with *T. gondii* seropositivity [114, 128–132], while others find no link. Perhaps certain types of epilepsy may be more associated with *T. gondii* infection.

6.5. Headaches and Migraine. Chronic *T. gondii* infection alters inflammatory cytokines, immunologic responses, and other biochemical responses such as the downregulation of

nitric oxide, some of which are posited to be a contributing factor to headaches [133–135]. A study of recurrent headaches in pediatric neurology patients found that 11% were positive for chronic *T. gondii* infection, and the majority of these patients had headaches most often in the frontal region [135]. A more recent study found that recurrent headaches were only statistically correlated with *T. gondii* on the basis of serointensity but were not correlated with seropositivity [136]. An earlier study found statistical significance between chronic *T. gondii* infection and migraine, describing 44% of patients experiencing migraine being positive for chronic *T. gondii* infection versus only 26% in healthy control subjects [134]. Multiple other studies support this association between *T. gondii* infection and migraines [137, 138]. However, while headaches and lymphadenopathy are the most commonly reported symptoms of acute toxoplasmosis, the relationship between recurrent headaches and migraine with chronic *T. gondii* infection is still uncertain [134].

6.6. Obsessive-Compulsive Disorder (OCD). Obsessive-compulsive disorder is thought to involve alterations in dopaminergic and serotonergic pathways [139]. In one study, the prevalence for anti-*T. gondii* IgG antibodies among OCD patients (48%) was found to be significantly higher than the prevalence in healthy volunteers (19%) [16]. Another study found a 2.5-fold increase of OCD prevalence among 7471 subjects with *T. gondii* chronic infection [140]. In a study conducted by Akaltun et al., there was a significant relationship between serum *T. gondii* IgG positivity and increased risk of OCD (4.9 fold) for children and adolescents [141], but a similar study of pediatric OCD found no statistical difference in seropositivity [142]. From a meta-analysis conducted by Chegeni, it was determined that 26% of patients with OCD were positive for chronic infection compared to those without OCD at 17% [143]. However, they described the limitations of the meta-analysis failing to fully represent the general population due to the samples being recruited through Facebook [143]. Other cross-section studies found no association between OCD and *T. gondii* infection [74, 111, 137]. Ultimately, the findings cumulatively suggest that there may be an association between OCD and chronic *T. gondii* infection in children, adolescents, and adults, but more studies must be done to confirm it.

6.7. Sleep. *T. gondii* infection reportedly affects neurotransmitter systems such as dopamine [48], GABA [52], serotonin [53], and noradrenaline. These neurotransmitters are involved in the sleep/wake cycle, and alterations in neurotransmitter concentrations or the sleep/wake cycle could lead to complications including psychiatric conditions [144], behavioral problems [145–147], car accidents [148], suicide, and cognitive deficits [149]. Sleep disturbances and disorders have long been known to affect mentality and are linked with depression [150]. In a study performed by Ahmad et al. attempting to link *T. gondii* infection and sleep disturbance, such as quality or quantity of sleep, no linkage was found [151]. There also was no association found between *T. gondii* and sleepiness or sleep apnea in obese patients [152]. Indeed, in a study conducted by Corona

et al., *T. gondii* seropositivity was linked to less sleep problems [153]. Taken together, there is no significant evidence of *T. gondii* associated with sleep disturbances.

6.8. Suicide. In 2016, nearly 45,000 Americans aged 10 or older died by suicide (Center for Disease Control and Prevention). Suicide is an increasing risk in the United States, especially for those mentally ill. The studies outlined in Table 1 suggest a relationship between suicide and *T. gondii* infection, as similarly reviewed by others recently [49, 154–160]. In a study by Okusaga et al., significance was found between *T. gondii* infection and suicide attempts in the subgroup of patients younger than 38 years old [49]. Yagmur et al. also found significance between suicide attempts and *T. gondii* infection in a population of infected individuals in the age group 24 ± 7.6 , whereas many of the other studies used populations of older individuals [154, 155]. Thus, the age of infection could be a contributing factor in the risk of individuals infected with *T. gondii* and suicide. Bak et al. also found *T. gondii*-seropositive patients to have a higher Hamilton depression rating score than seronegative suicide attempters [156]. While Alvarado-Esquivel et al. did find a possible association between high anti-*T. gondii* antibody levels and suicide attempts, Arling et al. found no significance between seropositivity and suicide [161, 162]. Continued studies, particularly those correlated with patient age, may show more association with suicide and *T. gondii* infection.

6.9. Parkinson's Disease. With *T. gondii*'s effect on dopamine neurotransmitter concentration, it has been proposed that *T. gondii* may play a role in the etiology of neurological diseases such as Parkinson's [20]. In Parkinson's disease (PD), dopamine levels are decreased and dopamine producing neurons are destroyed [81]. Vlayjinac et al. researched Parkinson's disease with its relationship to viral and bacterial infections and found that it was significantly related to mumps, scarlet fever, influenza, herpes simplex, and whooping cough infections but not related to measles, chicken pox, and tuberculosis. Miman et al. suggested that the inflammation and degeneration of dopamine-producing neurons caused by *T. gondii* could cause PD [23]. They found a significantly different prevalence for *T. gondii* antibodies in Parkinson's patients versus controls, 42% and 23%, respectively. Furthermore, Mahami-Oskouei et al. discovered a statistically significant association between Parkinson's disease and owning a cat ($p = 0.03$) although the *T. gondii* status of owned cats was not established. However, Mahami-Oskouei et al. found no significant association between IgG-positive titers and Parkinson's disease [163], and the meta-analysis conducted by Zhou et al. concluded that there is no linkage between PD risk and *T. gondii* infection [164]. While multiple studies suggest no significant linkage between PD and *T. gondii* infection [48, 165, 166], Ramezani et al. found higher anti-*Toxoplasma* IgG antibodies in patients with idiopathic PD. More studies may be valuable to examine the potential relationship between Parkinson's disease and *T. gondii*, as well as other infections.

6.10. Schizophrenia. The connection between schizophrenia and *T. gondii* infection has been studied since at least 1956 [167]. Patients with schizophrenia tend to have abnormal dopamine neurotransmitter levels as well as an abnormal glutamate and gamma aminobutyric acid (GABA) level [168]. Dopamine imbalance driven by the parasite may contribute to disease progression or intensity. The imbalance of the dopaminergic, mesolimbic, and mesocortical pathways, which are responsible for motivation, emotional responses, and reward, is also implicated in schizophrenia [169].

The immune system could also play an effect in the possible relation between *T. gondii* and schizophrenia [170]. Adaptive immune CD8⁺ T cells are important in controlling *T. gondii* infection and interact with MHC Class I alleles on infected cells. These CD8⁺ T cell responses may be relatively decreased following infection with some virulent strains of the parasite, such as the nontissue cyst generating RH strain [171, 172]. Downregulation of CD8⁺ T cell responses has been recognized as a commonality in individuals with schizophrenia [173]. The downregulation of CD8⁺ T cell responses caused by chronic *T. gondii* infection may be associated with the downregulation seen in individuals with schizophrenia. It should be noted that the MHC class I allele differs between hosts, which has been shown to affect the susceptibility to infection and disease significantly [174, 175].

In a meta-analysis of 38 studies, Torrey and Yolken determined the presence of *T. gondii* antibodies in patients to be an intermediate risk factor for schizophrenia [176]. Cetinkaya et al. determined that there were increased levels of serum anti-*T. gondii* IgG in patients with schizophrenia, while Leweke et al. found elevated anti-*T. gondii* antibodies in both serum and cerebrospinal fluid in patients with recent-onset schizophrenia [14, 15]. More recently, a study of 81,912 individuals from the Danish Blood Donor Study also found evidence that *T. gondii* and schizophrenia were statistically associated [177] while Muflikhah et al. also showed that seropositivity was higher at 69% for the group of patients with schizophrenia compared to the control group at 66%; however, the latter was not considered statistically significant [178]. In addition, Alipour et al. and Kezai et al. showed a significant difference of the seropositivity rate between controls and patients with schizophrenia: specifically, 67.7% in patients with schizophrenia vs. 37.1% in control patients and 70% in patients with schizophrenia vs 52.9% in controls [179, 180]. Significance has been further analyzed by the study done by Fond et al. finding that *T. gondii* is three times more frequent in the schizophrenia population than that in general populations [181]. Despite these possible associations, countries with a higher prevalence of *T. gondii* seropositivity have not shown a corresponding increased schizophrenia prevalence [182].

One component of these investigations is the association of *T. gondii* positivity, schizophrenia, and gender, but findings are inconsistent. For instance, Karabulut et al. showed no significant difference between *T. gondii* positivity and schizophrenia in respect to gender and age [183]. However, other studies have found a higher prevalence of *T. gondii* positivity in schizophrenic males compared to females [184, 185]. Yet, Khademvatan et al. showed the opposite

effect, finding a significant increase of seropositive schizophrenic females compared to seropositive schizophrenic males [186]. Ultimately, the linkage to gender must be further studied because a conclusive finding can be made. In regard to severity of symptoms, Eshili et al. notes that men with schizophrenia tend to have more severe negative and cognitive symptoms; additionally, patients have higher age of disease onset and an overall less favorable course [187].

Possible associations have also been found between maternal transmission of *T. gondii* infection and schizophrenia development in individuals. In a study conducted by Brown et al., subjects with schizophrenia spectrum disorders were 2.6-folds more likely to have mothers with detectable *T. gondii* IgG antibody titers [188]. In both prenatal and postnatal toxoplasmosis, there were linked findings for the risk factor of schizophrenia due to increase levels of homovanillic acid and dopamine which can be implicated with schizophrenia pathogenesis. Brown's 2011 review supports similar findings that prenatal infection of *T. gondii* may be a potential risk factor for schizophrenia [189]. Brown also suggests that differential consequences on fetal brain formation and development of schizophrenia may be due to the unique mechanisms of prenatal infection. Multiple other studies have related conclusions distinguishing the association between maternal prevalence and the increased risk of schizophrenia [190–194], including a suggestion that schizophrenia is more likely to develop with congenital toxoplasmosis than acquired toxoplasmosis based on behavioral testing [162]. More studies are needed to confirm this linkage.

Overall, the potential relationship with schizophrenia is the longest studied neurobehavioral disorder with regard to *T. gondii* infection, and the results taken together indicate a strong possible association between *T. gondii* infection and schizophrenia [195].

7. Conclusion

Chronic infection by *T. gondii* is considered lifelong in all hosts, including humans. Despite the number of medicinal therapies available to combat acute infection, evidence does not exist for a treatment consistently capable of clearing the tissue cyst stage in chronic infection, although new drug discovery is ongoing [10, 196, 197]. Thus, it is difficult to establish the causality of potential diseases reviewed here in humans. Furthermore, experimentally increasing *T. gondii* levels in mice or other models have been insufficiently studied to provide dose-dependent observations.

T. gondii seropositivity has been shown to differ significantly between countries, diverse topographical regions within the same country, and individuals of different ethnicities that live in similar regions [21, 198–204]. In considering linkages to *T. gondii* human infection, differences in lifestyle, cooccurring substance use disorders, varying differences in host species and/or strain, mode of infection (tissue cysts or oocysts), and/or timing of infection (in utero, childhood, or adulthood) may affect the findings of each study [7, 21, 205].

In conclusion, available studies on schizophrenia most consistently support a correlation of *T. gondii* and these disorders, while the literature on other disorders is mixed.

Therefore, the relationship between *T. gondii* infection and neurological or neurobehavioral disorders in humans should continue to be studied.

Disclosure

Funding agencies did not participate in the study design, data collection, analysis, or decision for publication.

Conflicts of Interest

The authors report no conflict of interest.

Acknowledgments

We recognize the U.S. National Institutes of Health (P20GM103427) and the University of Nebraska FUSE/-GRACA for support of this work.

References

- [1] A. Dalimi and A. Abdoli, "Latent toxoplasmosis and human," *Iranian Journal of Parasitology*, vol. 7, no. 1, pp. 1–17, 2012.
- [2] C. M. Marra, "Central nervous system infection with *Toxoplasma gondii*," *Handbook of Clinical Neurology*, vol. 152, pp. 117–122, 2018.
- [3] C. Yan, L. J. Liang, K. Y. Zheng, and X. Q. Zhu, "Impact of environmental factors on the emergence, transmission and distribution of *Toxoplasma gondii*," *Parasites & Vectors*, vol. 9, no. 1, p. 137, 2016.
- [4] J. J. Aramini, C. Stephen, J. P. Dubey, C. Engelstoft, H. Schwantje, and C. S. Ribble, "Potential contamination of drinking water with *Toxoplasma gondii* oocysts," *Epidemiology and Infection*, vol. 122, no. 2, pp. 305–315, 1999.
- [5] D. C. Grothen, S. J. Zach, and P. H. Davis, "Detection of intestinal pathogens in river, shore, and drinking water in Lima, Peru," *Journal of Genomics*, vol. 5, pp. 4–11, 2017.
- [6] J. B. McAuley, "Congenital Toxoplasmosis," *Journal of the Pediatric Infectious Diseases Society*, vol. 3, Supplement 1, pp. S30–S35, 2014.
- [7] A. G. Mangot, "Psychiatric aspects of toxoplasmosis: an Indian perspective," *Journal of Parasitic Diseases*, vol. 40, no. 4, pp. 1636–1639, 2016.
- [8] S. Fabiani, B. Pinto, U. Bonuccelli, and F. Bruschi, "Neurobiological studies on the relationship between toxoplasmosis and neuropsychiatric diseases," *Journal of the Neurological Sciences*, vol. 351, no. 1–2, pp. 3–8, 2015.
- [9] C. Konradt, N. Ueno, D. A. Christian et al., "Endothelial cells are a replicative niche for entry of *Toxoplasma gondii* to the central nervous system," *Nature Microbiology*, vol. 1, no. 3, p. 16001, 2016.
- [10] A. J. Neville, S. J. Zach, X. Wang et al., "Clinically available medicines demonstrating anti-toxoplasma activity," *Antimicrobial Agents and Chemotherapy*, vol. 59, no. 12, pp. 7161–7169, 2015.
- [11] A. Vyas and R. Sapolsky, "Manipulation of host behaviour by *Toxoplasma gondii*: what is the minimum a proposed proximate mechanism should explain?," *Folia Parasitologica*, vol. 57, no. 2, pp. 88–94, 2010.
- [12] V. O. Martinez, F. W. de Mendonça Lima, C. F. de Carvalho, and J. A. Menezes-Filho, "Toxoplasma gondii infection and

- behavioral outcomes in humans: a systematic review," *Parasitology Research*, vol. 117, no. 10, pp. 3059–3065, 2018.
- [13] E. F. Torrey and R. H. Yolken, "Toxoplasma oocysts as a public health problem," *Trends in Parasitology*, vol. 29, no. 8, pp. 380–384, 2013.
- [14] F. M. Leweke, C. W. Gerth, D. Koethe et al., "Antibodies to infectious agents in individuals with recent onset schizophrenia," *European Archives of Psychiatry and Clinical Neuroscience*, vol. 254, no. 1, pp. 4–8, 2004.
- [15] Z. Cetinkaya, S. Yazar, O. Gecici, and M. N. Namli, "Anti-Toxoplasma gondii antibodies in patients with schizophrenia—preliminary findings in a Turkish sample," *Schizophrenia Bulletin*, vol. 33, no. 3, pp. 789–791, 2007.
- [16] O. Miman, E. A. Mutlu, O. Ozcan, M. Atambay, R. Karlidag, and S. Unal, "Is there any role of *Toxoplasma gondii* in the etiology of obsessive-compulsive disorder?," *Psychiatry Research*, vol. 177, no. 1-2, pp. 263–265, 2010.
- [17] E. B. Ngoungou, D. Bhalla, A. Nzoghe, M. L. Dardé, and P. M. Preux, "Toxoplasmosis and epilepsy—systematic review and meta analysis," *PLoS Neglected Tropical Diseases*, vol. 9, no. 2, article e0003525, 2015.
- [18] B. S. Palmer, "Meta-analysis of three case controlled studies and an ecological study into the link between cryptogenic epilepsy and chronic toxoplasmosis infection," *Seizure*, vol. 16, no. 8, pp. 657–663, 2007.
- [19] R. H. McCusker and K. W. Kelley, "Immune-neural connections: how the immune system's response to infectious agents influences behavior," *The Journal of Experimental Biology*, vol. 216, no. 1, Part 1, pp. 84–98, 2013.
- [20] B. D. Pearce, D. Kruszon-Moran, and J. L. Jones, "The association of *Toxoplasma gondii* infection with neurocognitive deficits in a population-based analysis," *Social Psychiatry and Psychiatric Epidemiology*, vol. 49, no. 6, pp. 1001–1010, 2014.
- [21] A. Wadhawan, A. Dagdag, A. Duffy et al., "Positive association between *Toxoplasma gondii* IgG serointensity and current dysphoria/hopelessness scores in the Old Order Amish: a preliminary study," *Pteridines*, vol. 28, no. 3-4, pp. 185–194, 2017.
- [22] O. Y. Kusbeci, O. Miman, M. Yaman, O. C. Aktepe, and S. Yazar, "Could *Toxoplasma gondii* have any role in Alzheimer disease?," *Alzheimer Disease and Associated Disorders*, vol. 25, no. 1, pp. 1–3, 2011.
- [23] O. Miman, O. Y. Kusbeci, O. C. Aktepe, and Z. Cetinkaya, "The probable relation between *Toxoplasma gondii* and Parkinson's disease," *Neuroscience Letters*, vol. 475, no. 3, pp. 129–131, 2010.
- [24] J. P. Webster, "Rats, cats, people and parasites: the impact of latent toxoplasmosis on behaviour," *Microbes and Infection*, vol. 3, no. 12, pp. 1037–1045, 2001.
- [25] J. P. Webster, "The effect of *Toxoplasma gondii* on animal behavior: playing cat and mouse," *Schizophrenia Bulletin*, vol. 33, no. 3, pp. 752–756, 2007.
- [26] J. Flegr, "Influence of latent toxoplasmosis on the phenotype of intermediate hosts," *Folia Parasitologica*, vol. 57, no. 2, pp. 81–87, 2010.
- [27] J. Flegr, P. Lenochová, Z. Hodný, and M. Vondrová, "Fatal attraction phenomenon in humans: cat odour attractiveness increased for toxoplasma-infected men while decreased for infected women," *PLoS Neglected Tropical Diseases*, vol. 5, no. 11, article e1389, 2011.
- [28] H. Mahmoudvand, V. Sheibani, S. Shojaee et al., "Toxoplasma gondii Infection Potentiates Cognitive Impairments of Alzheimer's Disease in the BALB/c Mice," *The Journal of Parasitology*, vol. 102, no. 6, pp. 629–635, 2016.
- [29] P. K. House, A. Vyas, and R. Sapolsky, "Predator cat odors activate sexual arousal pathways in brains of *Toxoplasma gondii* infected rats," *PLoS One*, vol. 6, no. 8, article e23277, 2011.
- [30] M. Berenreiterová, J. Flegr, A. A. Kuběna, and P. Němec, "The distribution of *Toxoplasma gondii* cysts in the brain of a mouse with latent toxoplasmosis: implications for the behavioral manipulation hypothesis," *PLoS One*, vol. 6, no. 12, article e28925, 2011.
- [31] J. P. Webster and G. A. McConkey, "Toxoplasma gondii-altered host behaviour: clues as to mechanism of action," *Folia Parasitologica*, vol. 57, no. 2, pp. 95–104, 2010.
- [32] M. Gulinello, M. Acquarone, J. H. Kim et al., "Acquired infection with *Toxoplasma gondii* in adult mice results in sensorimotor deficits but normal cognitive behavior despite widespread brain pathology," *Microbes and Infection*, vol. 12, no. 7, pp. 528–537, 2010.
- [33] S. Ikemoto, "Brain reward circuitry beyond the mesolimbic dopamine system: a neurobiological theory," *Neuroscience and Biobehavioral Reviews*, vol. 35, no. 2, pp. 129–150, 2010.
- [34] S. Kittas, C. Kittas, P. Paizi-Biza, and L. Henry, "A histological and immunohistochemical study of the changes induced in the brains of white mice by infection with *Toxoplasma gondii*," *British Journal of Experimental Pathology*, vol. 65, no. 1, pp. 67–74, 1984.
- [35] I. Dellacasa-Lindberg, N. Hitziger, and A. Barragan, "Localized recrudescence of *Toxoplasma* infections in the central nervous system of immunocompromised mice assessed by in vivo bioluminescence imaging," *Microbes and Infection*, vol. 9, no. 11, pp. 1291–1298, 2007.
- [36] T. Wang, X. Sun, W. Qin et al., "From inflammatory reactions to neurotransmitter changes: Implications for understanding the neurobehavioral changes in mice chronically infected with *Toxoplasma gondii*," *Behavioural Brain Research*, vol. 359, pp. 737–748, 2019.
- [37] J. Hay, W. M. Hutchison, P. P. Aitken, and D. I. Graham, "The effect of congenital and adult-acquired *Toxoplasma* infections on activity and responsiveness to novel stimulation in mice," *Annals of Tropical Medicine and Parasitology*, vol. 77, no. 5, pp. 483–495, 1983.
- [38] J. Hay, P. P. Aitken, D. M. Hair, W. M. Hutchison, and D. I. Graham, "The effect of congenital *Toxoplasma* infection on mouse activity and relative preference for exposed areas over a series of trials," *Annals of Tropical Medicine and Parasitology*, vol. 78, no. 6, pp. 611–618, 1984.
- [39] D. Goodwin, T. C. Hrubec, B. G. Klein et al., "Congenital infection of mice with *Toxoplasma gondii* induces minimal change in behavior and no change in neurotransmitter concentrations," *The Journal of Parasitology*, vol. 98, no. 4, pp. 706–712, 2012.
- [40] T. Wang, M. Liu, X. J. Gao, Z. J. Zhao, X. G. Chen, and Z. R. Lun, "*Toxoplasma gondii*: The effects of infection at different stages of pregnancy on the offspring of mice," *Experimental Parasitology*, vol. 127, no. 1, pp. 107–112, 2011.
- [41] Z.-R. Wang and H. E. Bao, "Effect of *Toxoplasma gondii* prugnau strain infection in pregnant mice on the learning ability of the F1 generation," *Zhongguo Ji Sheng Chong Xue*

- Yu Ji Sheng Chong Bing Za Zhi*, vol. 31, no. 2, pp. 104–107, 2013.
- [42] O. A. Mendez and A. A. Koshy, “Toxoplasma gondii: entry, association, and physiological influence on the central nervous system,” *PLoS Pathogens*, vol. 13, no. 7, article e1006351, 2017.
- [43] T. C. Brightbill, M. J. D. Post, G. T. Hensley, and A. Ruiz, “MR of Toxoplasma encephalitis: signal characteristics on T2-weighted images and pathologic correlation,” *Journal of Computer Assisted Tomography*, vol. 20, no. 3, pp. 417–422, 1996.
- [44] G. A. McConkey, H. L. Martin, G. C. Bristow, and J. P. Webster, “Toxoplasma gondii infection and behaviour - location, location, location?,” *The Journal of Experimental Biology*, vol. 216, no. 1, pp. 113–119, 2013.
- [45] D. Samořłowicz, J. Twarowska-Małczyńska, A. Borowska-Solonyńko, Ł. A. Poniatowski, N. Sharma, and M. Olczak, “Presence of Toxoplasma gondii infection in brain as a potential cause of risky behavior: a report of 102 autopsy cases,” *European Journal of Clinical Microbiology & Infectious Diseases*, vol. 38, no. 2, pp. 305–317, 2019.
- [46] H. H. Stibbs, “Changes in brain concentrations of catecholamines and indoleamines in Toxoplasma gondii infected mice,” *Annals of Tropical Medicine and Parasitology*, vol. 79, no. 2, pp. 153–157, 1985.
- [47] S. Kamerkar and P. H. Davis, “Toxoplasma on the brain: understanding host-pathogen interactions in chronic CNS infection,” *Journal of Parasitology Research*, vol. 2012, Article ID 589295, 10 pages, 2012.
- [48] T. Çelik, Ö. Kamaşlı, C. Babür, M. Ö. Çevik, D. Öztuna, and S. Altınayar, “Is there a relationship between Toxoplasma gondii infection and idiopathic Parkinson’s disease?,” *Scandinavian Journal of Infectious Diseases*, vol. 42, no. 8, pp. 604–608, 2010.
- [49] O. Okusaga, P. Langenberg, A. Sleemi et al., “Toxoplasma gondii antibody titers and history of suicide attempts in patients with schizophrenia,” *Schizophrenia Research*, vol. 133, no. 1-3, pp. 150–155, 2011.
- [50] R. McFarland, Z. T. Wang, Y. Jouroukhin et al., “AAH2 gene is not required for dopamine-dependent neurochemical and behavioral abnormalities produced by Toxoplasma infection in mouse,” *Behavioural Brain Research*, vol. 347, pp. 193–200, 2018.
- [51] L. Peixoto, F. Chen, O. S. Harb et al., “Integrative genomic approaches highlight a family of parasite-specific kinases that regulate host responses,” *Cell Host & Microbe*, vol. 8, no. 2, pp. 208–218, 2010.
- [52] J. M. Fuks, R. B. G. Arrighi, J. M. Weidner et al., “GABAergic signaling is linked to a hypermigratory phenotype in dendritic cells infected by Toxoplasma gondii,” *PLoS Pathogens*, vol. 8, no. 12, article e1003051, 2012.
- [53] J. Gatkowska, M. Wiczorek, B. Dziadek, K. Dzitko, and H. Długowska, “Sex-dependent neurotransmitter level changes in brains of Toxoplasma gondii infected mice,” *Experimental Parasitology*, vol. 133, no. 1, pp. 1–7, 2013.
- [54] G. C. Dincel and H. T. Atmaca, “Nitric oxide production increases during Toxoplasma gondii encephalitis in mice,” *Experimental Parasitology*, vol. 156, pp. 104–112, 2015.
- [55] A. A. Tonin, A. S. da Silva, G. R. Thomé et al., “Influence of toxoplasmosis on acetylcholinesterase activity, nitric oxide levels and cellular lesion on the brain of mice,” *Pathology, Research and Practice*, vol. 210, no. 8, pp. 526–532, 2014.
- [56] N. Müller and M. J. Schwarz, “The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression,” *Molecular Psychiatry*, vol. 12, no. 11, pp. 988–1000, 2007.
- [57] G. Kannan, J. A. Crawford, C. Yang et al., “Anti-NMDA receptor autoantibodies and associated neurobehavioral pathology in mice are dependent on age of first exposure to Toxoplasma gondii,” *Neurobiology of Disease*, vol. 91, pp. 307–314, 2016.
- [58] D. Bottari, N. F. Troje, P. Ley, M. Hense, R. Kekunnaya, and B. Röder, “The neural development of the biological motion processing system does not rely on early visual input,” *Cortex*, vol. 71, pp. 359–367, 2015.
- [59] H. M. Ngô, Y. Zhou, H. Lorenzi et al., “Toxoplasma Modulates Signature Pathways of Human Epilepsy, Neurodegeneration & Cancer,” *Scientific Reports*, vol. 7, no. 1, p. 11496, 2017.
- [60] J. Havlíček, Z. Gašová, A. P. Smith, K. Zvára, and J. Flegr, “Decrease of psychomotor performance in subjects with latent “asymptomatic” toxoplasmosis,” *Parasitology*, vol. 122, no. 5, pp. 515–520, 2001.
- [61] C. Alvarado-Esquivel, A. Torres-Castorena, O. Liesenfeld, S. Estrada-Martínez, and J. D. Urbina-Álvarez, “High seroprevalence of Toxoplasma gondii infection in a subset of Mexican patients with work accidents and low socioeconomic status,” *Parasites & Vectors*, vol. 5, no. 1, p. 13, 2012.
- [62] J. Flegr, J. Havlíček, P. Kodym, M. Malý, and Z. Smahel, “Increased risk of traffic accidents in subjects with latent toxoplasmosis: a retrospective case-control study,” *BMC Infectious Diseases*, vol. 2, no. 1, p. 11, 2002.
- [63] B. Kocazeybek, Y. A. Oner, R. Turksoy et al., “Higher prevalence of toxoplasmosis in victims of traffic accidents suggest increased risk of traffic accident in Toxoplasma-infected inhabitants of Istanbul and its suburbs,” *Forensic Science International*, vol. 187, no. 1-3, pp. 103–108, 2009.
- [64] K. Yereli, I. C. Balcioglu, and A. Özbilgin, “Is Toxoplasma gondii a potential risk for traffic accidents in Turkey?,” *Forensic Science International*, vol. 163, no. 1-2, pp. 34–37, 2006.
- [65] J. Flegr, J. Lindová, and P. Kodym, “Sex-dependent toxoplasmosis-associated differences in testosterone concentration in humans,” *Parasitology*, vol. 135, no. 4, pp. 427–431, 2008.
- [66] H. Hodková, P. Kolbeková, A. Skallová, J. Lindová, and J. Flegr, “Higher perceived dominance in Toxoplasma infected men—a new evidence for role of increased level of testosterone in toxoplasmosis-associated changes in human behavior,” *Neuro Endocrinology Letters*, vol. 28, no. 2, pp. 110–114, 2007.
- [67] J. Flegr, M. Preiss, J. Klose, J. Havlíček, M. Vitáková, and P. Kodym, “Decreased level of psychobiological factor novelty seeking and lower intelligence in men latently infected with the protozoan parasite Toxoplasma gondii Dopamine, a missing link between schizophrenia and toxoplasmosis?,” *Biological Psychology*, vol. 63, no. 3, pp. 253–268, 2003.
- [68] A. Skallová, M. Novotná, P. Kolbeková et al. et al., “Decreased level of novelty seeking in blood donors infected with Toxoplasma,” *Neuro Endocrinology Letters*, vol. 26, no. 5, pp. 480–486, 2005.

- [69] J. Lindová, M. Novotná, J. Havlíček et al., “Gender differences in behavioural changes induced by latent toxoplasmosis,” *International Journal for Parasitology*, vol. 36, no. 14, pp. 1485–1492, 2006.
- [70] S. K. Johnson, M. A. Fitz, D. A. Lerner et al., “Risky business: linking *Toxoplasma gondii* infection and entrepreneurship behaviours across individuals and countries,” *Proceedings of the Biological Sciences*, vol. 285, no. 1883, p. 20180822, 2018.
- [71] J. Prandota, “Metabolic, immune, epigenetic, endocrine and phenotypic abnormalities found in individuals with autism spectrum disorders, Down syndrome and Alzheimer disease may be caused by congenital and/or acquired chronic cerebral toxoplasmosis,” *Research in Autism Spectrum Disorder*, vol. 5, no. 1, pp. 14–59, 2011.
- [72] C. E. Perry, S. D. Gale, L. Erickson et al., “Seroprevalence and serointensity of latent *Toxoplasma gondii* in a sample of elderly adults with and without Alzheimer disease,” *Alzheimer Disease and Associated Disorders*, vol. 30, no. 2, pp. 123–126, 2016.
- [73] N. Bouscaren, S. Pilleron, P. Mbelesso et al., “Prevalence of toxoplasmosis and its association with dementia in older adults in Central Africa: a result from the EPIDEMCA programme,” *Tropical Medicine and Parasitology*, vol. 23, no. 12, pp. 1304–1313, 2018.
- [74] W. Cong, W. Dong, L. Bai et al., “Seroprevalence and associated risk factors of *Toxoplasma gondii* infection in psychiatric patients: a case-control study in eastern China,” *Epidemiology and Infection*, vol. 143, no. 14, pp. 3103–3109, 2015.
- [75] L. Torres, S. A. Robinson, D. G. Kim, A. Yan, T. A. Cleland, and M. S. Bynoe, “*Toxoplasma gondii* alters NMDAR signaling and induces signs of Alzheimer’s disease in wild-type, C57BL/6 mice,” *Journal of Neuroinflammation*, vol. 15, no. 1, p. 57, 2018.
- [76] M. Mahami-Oskouei, F. Hamidi, M. Talebi et al., “Toxoplasmosis and Alzheimer: can *Toxoplasma gondii* really be introduced as a risk factor in etiology of Alzheimer?,” *Parasitology Research*, vol. 115, no. 8, pp. 3169–3174, 2016.
- [77] M. M. Rashno, S. Fallahi, and P. Bahrami, “Alzheimer’s disease and *Toxoplasma gondii* infection; seromolecular assess the possible link among patients,” *International Journal of Geriatric Psychiatry*, vol. 32, no. 2, pp. 232–234, 2017.
- [78] M. Menati Rashno, S. Fallahi, F. Kheirandish, S. Bagheri, M. H. Kayedi, and M. Birjandi, “Seroprevalence of *Toxoplasma gondii* infection in patients with Alzheimer’s disease,” *Archives of Clinical Infectious Diseases*, vol. 11, no. 3, article e60133, 2016.
- [79] V. L. Nimgaonkar, R. H. Yolken, T. Wang et al., “Temporal cognitive decline associated with exposure to infectious agents in a population-based, aging cohort,” *Alzheimer Disease and Associated Disorders*, vol. 30, no. 3, pp. 216–222, 2016.
- [80] C. Beste, S. Getzmann, P. D. Gajewski, K. Golka, and M. Falkenstein, “Latent *Toxoplasma gondii* infection leads to deficits in goal-directed behavior in healthy elderly,” *Neurobiology of Aging*, vol. 35, no. 5, pp. 1037–1044, 2014.
- [81] B.-K. Jung, K.-H. Pyo, K. Y. Shin et al., “*Toxoplasma gondii* infection in the brain inhibits neuronal degeneration and learning and memory impairments in a murine model of Alzheimer’s disease,” *PLoS One*, vol. 7, no. 3, article e33312, 2012.
- [82] M. A. Afifi, A. A. Jiman-Fatani, M. W. al-Rabia, N. H. al-Husainy, S. el Saadany, and W. Mayah, “More than an association: latent toxoplasmosis might provoke a local oxidative stress that triggers the development of bipolar disorder,” *Journal of Microscopy and Ultrastructure*, vol. 6, no. 3, pp. 139–144, 2018.
- [83] C. del Grande, E. Schiavi, I. Masci et al., “Toxoplasmosis in a cohort of Italian patients with bipolar and psychotic Disorders,” *The Journal of Nervous and Mental Disease*, vol. 208, no. 2, pp. 118–126, 2020.
- [84] N. Hamdani, D. Bengoufa, O. Godin et al., “Immunoglobulin sub-class distribution in bipolar disorder and schizophrenia: potential relationship with latent *Toxoplasma gondii* infection,” *BMC Psychiatry*, vol. 18, no. 1, p. 239, 2018.
- [85] B. D. Pearce, D. Kruszon-Moran, and J. L. Jones, “The Relationship Between *Toxoplasma Gondii* Infection and Mood Disorders in the Third National Health and Nutrition Survey,” *Biological Psychiatry*, vol. 72, no. 4, pp. 290–295, 2012.
- [86] N. Hamdani, C. Daban-Huard, M. Lajnef et al., “Relationship between *Toxoplasma gondii* infection and bipolar disorder in a French sample,” *Journal of Affective Disorders*, vol. 148, no. 2-3, pp. 444–448, 2013.
- [87] C. Alvarado-Esquivel, S. Estrada-Martínez, and A. R. Pérez-Alamos, “A case-control seroprevalence study on the association between *Toxoplasma gondii* infection and bipolar disorder,” *Frontiers in Psychiatry*, vol. 10, p. 766, 2019.
- [88] M. A. Frye, B. J. Coombes, S. L. McElroy et al., “Association of cytomegalovirus and *Toxoplasma gondii* antibody titers with bipolar disorder,” *JAMA Psychiatry*, vol. 76, no. 12, pp. 1285–1293, 2019.
- [89] N. Hamdani, C. Daban-Huard, M. Lajnef et al., “Cognitive deterioration among bipolar disorder patients infected by *Toxoplasma gondii* is correlated to interleukin 6 levels,” *Journal of Affective Disorders*, vol. 179, pp. 161–166, 2015.
- [90] J. Oliveira, R. Kazma, E. le Floch et al., “*Toxoplasma gondii* exposure may modulate the influence of TLR2 genetic variation on bipolar disorder: a gene–environment interaction study,” *International Journal of Bipolar Disorders*, vol. 4, no. 1, p. 11, 2016.
- [91] P. B. Mortensen, C. B. Pedersen, J. J. McGrath et al., “Neonatal antibodies to infectious agents and risk of bipolar disorder: a population-based case-control study,” *Bipolar Disorders*, vol. 13, no. 7-8, pp. 624–629, 2011.
- [92] O. Stich, T. A. Andres, C. M. Gross, S. I. Gerber, S. Rauer, and J. M. Langosch, “An observational study of inflammation in the central nervous system in patients with bipolar disorder,” *Bipolar Disorders*, vol. 17, no. 3, pp. 291–302, 2015.
- [93] A. Chaudhury and B. V. Ramana, “Schizophrenia and bipolar disorders: the *Toxoplasma* connection,” *Tropenmedizin und Parasitologie*, vol. 9, no. 2, pp. 71–76, 2019.
- [94] D. Freedman, Y. Bao, L. Shen, C. A. Schaefer, and A. S. Brown, “Maternal *T. gondii*, offspring bipolar disorder and neurocognition,” *Psychiatry Research*, vol. 243, pp. 382–389, 2016.
- [95] C. del Grande, L. Galli, E. Schiavi, L. Dell’Osso, and F. Bruschi, “Is *Toxoplasma gondii* a trigger of bipolar disorder?,” *Pathogens*, vol. 6, no. 1, p. 3, 2017.
- [96] D. G. Goodwin, J. S. Strobl, and D. S. Lindsay, “Evaluation of five antischizophrenic agents against *Toxoplasma gondii* in human cell cultures,” *The Journal of Parasitology*, vol. 97, no. 1, pp. 148–151, 2011.

- [97] G. Fond, A. Macgregor, R. Tamouza et al., "Comparative analysis of anti-toxoplasmic activity of antipsychotic drugs and valproate," *European Archives of Psychiatry and Clinical Neuroscience*, vol. 264, no. 2, pp. 179–183, 2014.
- [98] G. Fond, J.-A. Micoulaud-Franchi, L. Brunel et al., "Innovative mechanisms of action for pharmaceutical cognitive enhancement: a systematic review," *Psychiatry Research*, vol. 229, no. 1-2, pp. 12–20, 2015.
- [99] G. Fond, L. Boyer, A. Gaman et al., "Treatment with anti-toxoplasmic activity (TATA) for toxoplasma positive patients with bipolar disorders or schizophrenia: a cross-sectional study," *Journal of Psychiatric Research*, vol. 63, pp. 58–64, 2015.
- [100] S. D. Chorlton, "Toxoplasma gondii and schizophrenia: a review of published RCTs," *Parasitology Research*, vol. 116, no. 7, pp. 1793–1799, 2017.
- [101] C. Alvarado-Esquivel, L. F. Sánchez-Anguiano, J. Hernández-Tinoco et al., "Toxoplasma gondii infection and depression: a case-control seroprevalence study," *European Journal of Microbiology and Immunology*, vol. 6, no. 2, pp. 85–89, 2016.
- [102] A. R. Duffy, T. M. Beckie, L. A. Brenner et al., "Relationship between Toxoplasma gondii and mood disturbance in women veterans," *Military Medicine*, vol. 180, no. 6, pp. 621–625, 2015.
- [103] Ş. Yalın Sapmaz, S. Şen, Y. Özkan, and H. Kandemir, "Relationship between Toxoplasma gondii seropositivity and depression in children and adolescents," *Psychiatry Research*, vol. 278, pp. 263–267, 2019.
- [104] S. Nasirpour, F. Kheirandish, and S. Fallahi, "Depression and Toxoplasma gondii infection: assess the possible relationship through a seromolecular case-control study," *Archives of Microbiology*, vol. 202, no. 10, pp. 2689–2695, 2020.
- [105] M. W. Groër, R. H. Yolken, J. Xiao et al., "Prenatal depression and anxiety in Toxoplasma gondii-positive women," *American Journal of Obstetrics and Gynecology*, vol. 204, no. 5, pp. 433.e1–433.e7, 2011.
- [106] M. E. Mahmoud, R. Fereig, and Y. Nishikawa, "Involvement of host defense mechanisms against Toxoplasma gondii infection in anhedonic and despair-like behaviors in mice," *Infection and Immunity*, vol. 85, no. 4, 2017.
- [107] I. F. Rehan, M. E. Mahmoud, D. Salman et al., "Sialylated N-glycan profile during acute and chronic infections with Toxoplasma gondii in mice," *Scientific Reports*, vol. 10, no. 1, p. 3809, 2020.
- [108] S. D. Gale, A. N. Berrett, B. Brown, L. D. Erickson, and D. W. Hedges, "No association between current depression and latent toxoplasmosis in adults," *Folia Parasitologica*, vol. 63, 2016.
- [109] C. Alvarado-Esquivel, A. L. Martínez-Martínez, L. F. Sánchez-Anguiano et al., "Lack of association between Toxoplasma gondii exposure and depression in pregnant women: a case-control study," *BMC Infectious Diseases*, vol. 17, no. 1, p. 190, 2017.
- [110] J. Flegr and Z. Hodný, "Cat scratches, not bites, are associated with unipolar depression—cross-sectional study," *Parasites & Vectors*, vol. 9, no. 1, p. 8, 2016.
- [111] W. M. Zaki, R. Y. Hofdi, A. A. Shebiley, Z. A. Saadi, and A. H. Ageel, "Seroprevalence of Toxoplasma gondii infection and its associated risk factors in neuropsychiatric patients in Jazan Province, Saudi Arabia," *Journal of the Egyptian Society of Parasitology*, vol. 46, no. 3, pp. 467–474, 2016.
- [112] M. Nourollahpour Shiadeh, A. Rostami, B. D. Pearce et al., "The correlation between Toxoplasma gondii infection and prenatal depression in pregnant women," *European Journal of Clinical Microbiology & Infectious Diseases*, vol. 35, no. 11, pp. 1829–1835, 2016.
- [113] S. Shahnaz, A. Laila, and T. M. Fatemeh, "Effects of Toxoplasma gondii infection on plasma testosterone and cortisol level and stress index on patients referred to Sina hospital, Tehran," *Jundishapur Journal of Microbiology*, vol. 4, no. 3, pp. 167–173, 2011.
- [114] N. F. Abd el-Aal, M. Saber, and N. Fawzy, "Sero-prevalence of anti-Toxoplasma gondii antibodies among patients with neuropsychiatric disorders: epilepsy and depression," *Journal of the Egyptian Society of Parasitology*, vol. 46, no. 3, pp. 729–736, 2016.
- [115] F. Haroon, U. Händel, F. Angenstein et al., "Toxoplasma gondii actively inhibits neuronal function in chronically infected mice," *PLoS One*, vol. 7, no. 4, article e35516, 2012.
- [116] Ö. Miman, Ö. Özcan, S. Ünal, and M. Atambay, "Toxoplasma gondii - obsessive-compulsive disorder relationship: is it different in children?," *Nordic Journal of Psychiatry*, vol. 72, no. 7, pp. 501–505, 2018.
- [117] A. Akyol, B. Bicerol, S. Ertug, H. Ertabaklar, and N. Kiylioglu, "Epilepsy and seropositivity rates of Toxocara canis and Toxoplasma gondii," *Seizure*, vol. 16, no. 3, pp. 233–237, 2007.
- [118] J. Babaie, M. Sayyah, K. Gharagozli, E. Mostafavi, and M. Golkar, "Seroepidemiological study of Toxoplasma gondii infection in a population of Iranian epileptic patients," *EXCLI Journal*, vol. 16, pp. 256–264, 2017.
- [119] E. W. Stommel, R. Seguin, V. M. Thadani et al., "Cryptogenic epilepsy: an infectious etiology?," *Epilepsia*, vol. 42, no. 3, pp. 436–438, 2001.
- [120] J. Babaie, M. Sayyah, S. Choopani, T. Asgari, M. Golkar, and K. Gharagozli, "Toxoplasmosis accelerates acquisition of epilepsy in rats undergoing chemical kindling," *Epilepsy Research*, vol. 135, pp. 137–142, 2017.
- [121] J. Flegr, "Effects of toxoplasma on human behavior," *Schizophrenia Bulletin*, vol. 33, no. 3, pp. 757–760, 2007.
- [122] Z. Eslamirad, R. Hajhossein, B. Ghorbanzadeh, M. Alimohammadi, M. Mosayebi, and M. Didehdar, "Effects of Toxoplasma gondii infection in level of serum testosterone in males with chronic toxoplasmosis," *Iranian Journal of Parasitology*, vol. 8, no. 4, pp. 622–626, 2013.
- [123] A. Abdoli and A. Dalimi, "Are there any relationships between latent Toxoplasma gondii infection, testosterone elevation, and risk of autism spectrum disorder?," *Frontiers in Behavioral Neuroscience*, vol. 8, 2014.
- [124] T. D. Purves-Tyson, S. J. Owens, K. L. Double, R. Desai, D. J. Handelsman, and C. S. Weickert, "Testosterone induces molecular changes in dopamine signaling pathway molecules in the adolescent male rat nigrostriatal pathway," *PLoS One*, vol. 9, no. 3, article e91151, 2014.
- [125] C. Alvarado-Esquivel, Y. D. R. Rico-Almochantaf, J. Hernández-Tinoco et al., "Toxoplasma gondii exposure and epilepsy: a matched case-control study in a public hospital in northern Mexico," *SAGE Open Medicine*, vol. 6, 2018.
- [126] L. Xiao and J. B. Becker, "Effects of estrogen agonists on amphetamine-stimulated striatal dopamine release," *Synapse*, vol. 29, no. 4, pp. 379–391, 1998.
- [127] W. K. Jeong, B. E. Joo, J. H. Seo, J. K. Mun, J. Kim, and D. W. Seo, "Mesial temporal lobe epilepsy in congenital

- toxoplasmosis: a case report,” *Journal of Epilepsy Research*, vol. 5, no. 1, pp. 25–28, 2015.
- [128] N. Labeeb el-Tantawy, H. Ahmed el-Nahas, D. Abdel-Badie Salem, N. Abdel-Badie Salem, and B. M. Hasaneen, “Seroprevalence of *Toxoplasma Gondii* and *Toxocara Spp* in children with cryptogenic epilepsy,” *American Journal of Infectious Diseases and Microbiology*, vol. 1, no. 5, pp. 92–95, 2013.
- [129] S. Allahdin, S. Khademvatan, A. Rafiei, A. Momen, and R. Rafiei, “Frequency of *Toxoplasma* and *Toxocara sp.* antibodies in epileptic patients, in South Western Iran,” *Iranian Journal of Child Neurology*, vol. 9, no. 4, pp. 32–40, 2015.
- [130] M. A. Eraky, S. Abdel-Hady, and K. F. Abdallah, “Seropositivity of *Toxoplasma gondii* and *Toxocara spp.* in children with cryptogenic epilepsy, Benha, Egypt,” *The Korean Journal of Parasitology*, vol. 54, no. 3, pp. 335–338, 2016.
- [131] M. Zibaei, Z. Zamani, C. Atefeh, K. Anbari, and M. R. Nazer, “*Toxoplasma* infection and epilepsy: a case-control study in Iran,” *Neurol Asia*, vol. 16, no. 4, pp. 299–302, 2011.
- [132] S. Yazar, F. Arman, Ş. Yalçın, F. Demirtaş, O. Yaman, and I. Şahin, “Investigation of probable relationship between *Toxoplasma gondii* and cryptogenic epilepsy,” *Seizure*, vol. 12, no. 2, pp. 107–109, 2003.
- [133] J. Prandota, “Recurrent headache as the main symptom of acquired cerebral toxoplasmosis in nonhuman immunodeficiency virus-infected subjects with no lymphadenopathy: the parasite may be responsible for the neurogenic inflammation postulated as a cause of different types of headaches,” *American Journal of Therapeutics*, vol. 14, no. 1, pp. 63–105, 2007.
- [134] E. Koseoglu, I. Koc, and S. Yazar, “Is *Toxoplasma gondii* a Causal Agent in Migraine?,” *The American Journal of the Medical Sciences*, vol. 338, no. 2, pp. 120–122, 2009.
- [135] J. Prandota, A. Gryglas, A. Fuglewicz et al., “Recurrent headaches may be caused by cerebral toxoplasmosis,” *World Journal of Clinical Pediatrics*, vol. 3, no. 3, pp. 59–68, 2014.
- [136] C. Alvarado-Esquivel, Y. D. R. Rico-Almochantaf, L. F. Sanchez-Anguiano et al., “*Toxoplasma gondii* Infection and headache: a matched case-control study in a public hospital in Durango city, Mexico,” *Journal of Clinical Medical Research*, vol. 10, no. 1, pp. 27–31, 2018.
- [137] J. Flegr and D. Q. Escudero, “Impaired health status and increased incidence of diseases in *Toxoplasma*-seropositive subjects – an explorative cross-sectional study,” *Parasitology*, vol. 143, no. 14, pp. 1974–1989, 2016.
- [138] N. Jouyani, M. T. Ahady, and V. Abbasi, “Serum level of anti-*Toxoplasma gondii* IgG among the individuals with/without migraine,” *Journal of Shahid Sadoughi University of Medical Sciences*, vol. 28, no. 1, 2020.
- [139] D. Denys, J. Zohar, and H. G. M. Westenberg, “The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence,” *The Journal of Clinical Psychiatry*, vol. 65, Supplement 14, pp. 11–17, 2004.
- [140] J. Flegr and J. Horáček, “*Toxoplasma*-infected subjects report an obsessive-compulsive disorder diagnosis more often and score higher in obsessive-compulsive inventory,” *European Psychiatry*, vol. 40, pp. 82–87, 2017.
- [141] İ. Akaltun, S. S. Kara, and T. Kara, “The relationship between *Toxoplasma gondii* IgG antibodies and generalized anxiety disorder and obsessive-compulsive disorder in children and adolescents: a new approach,” *Nordic Journal of Psychiatry*, vol. 72, no. 1, pp. 57–62, 2018.
- [142] N. Çakın Memik, G. Sönmez Tamer, H. Ünver, and Ö. Yıldız Gündoğdu, “The relationship between pediatric obsessive compulsive disorder and *Toxoplasma gondii*,” *Journal of Obsessive-Compulsive and Related Disorders*, vol. 7, pp. 24–28, 2015.
- [143] T. Nayeri Chegeni, S. Sarvi, A. Amouei et al., “Relationship between toxoplasmosis and obsessive compulsive disorder: a systematic review and meta-analysis,” *PLoS Neglected Tropical Diseases*, vol. 13, no. 4, article e0007306, 2019.
- [144] D. E. Ford and D. B. Kamerow, “Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention?,” *Journal of the American Medical Association*, vol. 262, no. 11, pp. 1479–1484, 1989.
- [145] M. A. Carskadon, “Patterns of sleep and sleepiness in adolescents,” *Pediatrician*, vol. 17, no. 1, pp. 5–12, 1990.
- [146] D. N. Morrison, R. McGee, and W. R. Stanton, “Sleep problems in adolescence,” *Journal of the American Academy of Child and Adolescent Psychiatry*, vol. 31, no. 1, pp. 94–99, 1992.
- [147] A. R. Wolfson and M. A. Carskadon, “Sleep schedules and daytime functioning in adolescents,” *Child Development*, vol. 69, no. 4, pp. 875–887, 1998.
- [148] T. Young, J. Blustein, L. Finn, and M. Palta, “Sleep-disordered breathing and motor vehicle accidents in a population-based sample of employed adults,” *Sleep*, vol. 20, no. 8, pp. 608–613, 1997.
- [149] D. J. Foley, K. Masaki, L. White, E. K. Larkin, A. Monjan, and S. Redline, “Sleep-disordered breathing and cognitive impairment in elderly Japanese-American men,” *Sleep*, vol. 26, no. 5, pp. 596–599, 2003.
- [150] D. Nutt, S. Wilson, and L. Paterson, “Sleep disorders as core symptoms of depression,” *Dialogues in Clinical Neuroscience*, vol. 10, no. 3, pp. 329–336, 2008.
- [151] Z. Ahmad, Y. W. Moustafa, J. W. Stiller et al., “Sleep onset insomnia, daytime sleepiness and sleep duration in relationship to *Toxoplasma gondii* IgG seropositivity and serointensity,” *Pteridines*, vol. 28, no. 3-4, pp. 195–204, 2017.
- [152] C. Dard, S. Bailly, J.-L. Pépin et al., “Chronic toxoplasmosis and sleepiness in obstructive sleep apnea: is there a link?,” *PLoS One*, vol. 15, no. 7, article e0235463, 2020.
- [153] C. C. Corona, M. Zhang, A. Wadhawan et al., “*Toxoplasma gondii* IgG associations with sleep-wake problems, sleep duration and timing,” *Pteridines*, vol. 30, no. 1, pp. 1–9, 2019.
- [154] F. Yagmur, S. Yazar, H. O. Temel, and M. Cavusoglu, “May *Toxoplasma gondii* increase suicide attempt-preliminary results in Turkish subjects?,” *Forensic Science International*, vol. 199, no. 1-3, pp. 15–17, 2010.
- [155] V. J. Ling, D. Lester, P. B. Mortensen, P. W. Langenberg, and T. T. Postolache, “*Toxoplasma gondii* seropositivity and suicide rates in women,” *The Journal of Nervous and Mental Disease*, vol. 199, no. 7, pp. 440–444, 2011.
- [156] J. Bak, S.-H. Shim, Y.-J. Kwon et al., “The Association between suicide attempts and *Toxoplasma gondii* Infection,” *Clinical Psychopharmacology and Neuroscience*, vol. 16, no. 1, pp. 95–102, 2018.
- [157] S. A. Sari and A. Kara, “Association of suicide attempt with seroprevalence of *Toxoplasma gondii* in adolescents,” *The*

- Journal of Nervous and Mental Disease*, vol. 207, no. 12, pp. 1025–1030, 2019.
- [158] W. Coryell, H. Wilcox, S. J. Evans et al., “Latent infection, inflammatory markers and suicide attempt history in depressive disorders,” *Journal of Affective Disorders*, vol. 270, pp. 97–101, 2020.
- [159] F. Dickerson, H. C. Wilcox, M. Adamos et al., “Suicide attempts and markers of immune response in individuals with serious mental illness,” *Journal of Psychiatric Research*, vol. 87, pp. 37–43, 2017.
- [160] M. Ansari-Lari, H. Farashbandi, and F. Mohammadi, “Association of *Toxoplasma gondii* infection with schizophrenia and its relationship with suicide attempts in these patients,” *Tropical Medicine & International Health*, vol. 22, no. 10, pp. 1322–1327, 2017.
- [161] T. A. Arling, R. H. Yolken, M. Lapidus et al., “*Toxoplasma gondii* antibody titers and history of suicide attempts in patients with recurrent mood disorders,” *The Journal of Nervous and Mental Disease*, vol. 197, no. 12, pp. 905–908, 2009.
- [162] C. Alvarado-Esquivel, L. F. Sánchez-Anguiano, C. A. Arnaud-Gil et al., “*Toxoplasma gondii* infection and suicide Attempts,” *The Journal of Nervous and Mental Disease*, vol. 201, no. 11, pp. 948–952, 2013.
- [163] M. Mahami Oskouei, F. Hamidi, M. Talebi et al., “The correlation between *Toxoplasma gondii* infection and Parkinson’s disease: a case-control study,” *Journal of Parasitic Diseases*, vol. 40, no. 3, pp. 872–876, 2016.
- [164] Z. Zhou, R. Zhou, K. Li et al., “The association between *Toxoplasma gondii* infection and risk of Parkinson’s disease: a systematic review and meta-analysis,” *BioMed Research International*, vol. 2019, Article ID 8186017, 8 pages, 2019.
- [165] S. Fallahi, A. Rostami, M. Birjandi, N. Zebardast, F. Kheirandish, and A. Spotin, “Parkinson’s disease and *Toxoplasma gondii* infection: Sero-molecular assess the possible link among patients,” *Acta Tropica*, vol. 173, pp. 97–101, 2017.
- [166] W. M. el Gendy, N. A. el Azeem Yassen, H. A. el Rahman Fayed, M. A. Hasby Saad, and A. A. R. Daoud, “Is there a relationship between *Toxoplasma gondii* immunoglobulin G seropositivity and idiopathic Parkinson’s disease and does it have a correlation with serum cortisol level?,” *Tanta Medical Journal*, vol. 45, no. 1, p. 29, 2017.
- [167] E. F. Torrey and R. H. Yolken, “*Toxoplasma gondii* and schizophrenia,” *Emerging Infectious Diseases*, vol. 9, no. 11, pp. 1375–1380, 2003.
- [168] K. R. Patel, J. Cherian, K. Gohil, and D. Atkinson, “Schizophrenia: overview and treatment options,” *P & T: a Peer-reviewed Journal for Formulary Management*, vol. 39, no. 9, pp. 638–645, 2014.
- [169] S. E. Hyman, R. C. Malenka, and E. J. Nestler, “Neural mechanisms of addiction: the role of reward-related learning and memory,” *Annual Review of Neuroscience*, vol. 29, no. 1, pp. 565–598, 2006.
- [170] S. A. Henriquez, R. Brett, J. Alexander, J. Pratt, and C. W. Roberts, “Neuropsychiatric disease and *Toxoplasma gondii* infection,” *Neuroimmunomodulation*, vol. 16, no. 2, pp. 122–133, 2009.
- [171] E. D. Tait, K. A. Jordan, C. D. Dupont et al., “Virulence of *Toxoplasma gondii* associated with distinct dendritic cell responses and reduced numbers of activated CD8+T cells,” *Journal of Immunology*, vol. 185, no. 3, pp. 1502–1512, 2010.
- [172] R. Bhadra, J. P. Gigley, L. M. Weiss, and I. A. Khan, “Control of *Toxoplasma* reactivation by rescue of dysfunctional CD8+ T-cell response via PD-1-PDL-1 blockade,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 108, no. 22, pp. 9196–9201, 2011.
- [173] R. Bhadra, D. A. Cobb, L. M. Weiss, and I. A. Khan, “Psychiatric disorders in toxoplasma seropositive patients—the CD8 connection,” *Schizophrenia Bulletin*, vol. 39, no. 3, pp. 485–489, 2013.
- [174] C. R. Brown, C. A. Hunter, R. G. Estes et al., “Definitive identification of a gene that confers resistance against *Toxoplasma* cyst burden and encephalitis,” *Immunology*, vol. 85, no. 3, pp. 419–428, 1995.
- [175] Y. Suzuki, J. Clafin, X. Wang, A. Lengi, and T. Kikuchi, “Microglia and macrophages as innate producers of interferon-gamma in the brain following infection with *Toxoplasma gondii*,” *International Journal for Parasitology*, vol. 35, no. 1, pp. 83–90, 2005.
- [176] E. F. Torrey and R. H. Yolken, “Schizophrenia and toxoplasmosis,” *Schizophrenia Bulletin*, vol. 33, no. 3, pp. 727–728, 2007.
- [177] K. S. Burgdorf, B. B. Trabjerg, M. G. Pedersen et al., “Large-scale study of *Toxoplasma* and Cytomegalovirus shows an association between infection and serious psychiatric disorders,” *Brain, Behavior, and Immunity*, vol. 79, pp. 152–158, 2019.
- [178] N. D. Muflikhah, Supargiyono, and W. T. Artama, “Seroprevalence and risk factor of toxoplasmosis in schizophrenia patients referred to Grhasia psychiatric hospital, Yogyakarta, Indonesia,” *African Journal of Infectious Diseases*, vol. 12, 1 Supplement, pp. 76–82, 2018.
- [179] A. Alipour, S. Shojaee, M. Mohebbi, M. Tehranidoost, F. Abdi Masoleh, and H. Keshavarz, “*Toxoplasma* infection in schizophrenia patients: a comparative study with control group,” *Iranian Journal of Parasitology*, vol. 6, no. 2, pp. 31–37, 2011.
- [180] A. M. Kezai, C. Lecoecur, D. Hot, M. Bounechada, M. L. Alouani, and S. Marion, “Association between schizophrenia and *Toxoplasma gondii* infection in Algeria,” *Psychiatry Research*, vol. 291, p. 113293, 2020.
- [181] G. Fond, L. Boyer, F. Schürhoff et al., “Latent toxoplasma infection in real-world schizophrenia: results from the national FACE-SZ cohort,” *Schizophrenia Research*, vol. 201, pp. 373–380, 2018.
- [182] E. L. Messias, C. Y. Chen, and W. W. Eaton, “Epidemiology of schizophrenia: review of findings and myths,” *The Psychiatric Clinics of North America*, vol. 30, no. 3, pp. 323–338, 2007.
- [183] N. Karabulut, S. Bilgiç, M. G. Gürok, and F. Karaboğa, “Is there any role of latent toxoplasmosis in schizophrenia disease?,” *Journal of the Chinese Medical Association*, vol. 78, no. 9, pp. 533–537, 2015.
- [184] J. Flegr, L. Příplatova, R. Hampl, M. Biciková, D. Ripova, and P. Mohr, “Difference of neuro- and immunomodulatory steroids and selected hormone and lipid concentrations between *Toxoplasma*-free and *Toxoplasma*-infected but not CMV-free and CMV-infected schizophrenia patients,” *Neuro Endocrinology Letters*, vol. 35, no. 1, pp. 20–27, 2014.
- [185] N. H. al-Hussainy, A. M. al-saedi, J. H. al-lehaibi, Y. A. al-lehaibi, Y. M. al-Sehli, and M. A. Afifi, “Serological evidences link toxoplasmosis with schizophrenia and major depression disorder,” *Journal of Microscopy and Ultrastructure*, vol. 3, no. 3, pp. 148–153, 2015.

- [186] S. Khademvatan, J. Saki, N. Khajeddin et al., "Toxoplasma gondii exposure and the risk of schizophrenia," *Jundishapur Journal of Microbiology*, vol. 7, no. 11, 2014.
- [187] A. Eshhili, S. Thabet, A. Jemli et al., "Toxoplasma gondii infection in schizophrenia and associated clinical features," *Psychiatry Research*, vol. 245, pp. 327–332, 2016.
- [188] A. S. Brown, C. A. Schaefer, C. P. Quesenberry Jr., L. Liu, V. P. Babulas, and E. S. Susser, "Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring," *The American Journal of Psychiatry*, vol. 162, no. 4, pp. 767–773, 2005.
- [189] A. S. Brown, "Exposure to prenatal infection and risk of schizophrenia," *Frontiers in Psychiatry*, vol. 2, p. 63, 2011.
- [190] J. Xiao, S. L. Buka, T. D. Cannon et al., "Serological pattern consistent with infection with type I *Toxoplasma gondii* in mothers and risk of psychosis among adult offspring," *Microbes and Infection*, vol. 11, no. 13, pp. 1011–1018, 2009.
- [191] P. B. Mortensen, B. Nørgaard-Pedersen, B. L. Waltoft et al., "*Toxoplasma gondii* as a Risk Factor for Early-Onset Schizophrenia: Analysis of Filter Paper Blood Samples Obtained at Birth," *Biological Psychiatry*, vol. 61, no. 5, pp. 688–693, 2007.
- [192] P. B. Mortensen, B. Nørgaard-Pedersen, B. L. Waltoft, T. L. Sorensen, D. Hougaard, and R. H. Yolken, "Early infections of *Toxoplasma gondii* and the later development of schizophrenia," *Schizophrenia Bulletin*, vol. 33, no. 3, pp. 741–744, 2007.
- [193] V. B. Carruthers and Y. Suzuki, "Effects of *Toxoplasma gondii* infection on the brain," *Schizophrenia Bulletin*, vol. 33, no. 3, pp. 745–751, 2007.
- [194] R. H. Yolken and E. F. Torrey, "Are some cases of psychosis caused by microbial agents? A review of the evidence," *Molecular Psychiatry*, vol. 13, no. 5, pp. 470–479, 2008.
- [195] A. J. Fuglewicz, P. Piotrowski, and A. Stodolak, "Relationship between toxoplasmosis and schizophrenia: a review," *Advances in Clinical and Experimental Medicine*, vol. 26, no. 6, pp. 1033–1038, 2017.
- [196] M. M. McFarland, S. J. Zach, X. Wang et al., "Review of experimental compounds demonstrating anti-*Toxoplasma* activity," *Antimicrobial Agents and Chemotherapy*, vol. 60, no. 12, pp. 7017–7034, 2016.
- [197] A. G. Sanford, T. T. Schulze, L. P. Potluri et al., "Novel *Toxoplasma gondii* inhibitor chemotypes," *Parasitology International*, vol. 67, no. 2, pp. 107–111, 2018.
- [198] G. Pappas, N. Roussos, and M. E. Falagas, "Toxoplasmosis snapshots: Global status of *Toxoplasma gondii* seroprevalence and implications for pregnancy and congenital toxoplasmosis," *International Journal for Parasitology*, vol. 39, no. 12, pp. 1385–1394, 2009.
- [199] A. M. Tenter, A. R. Heckeroth, and L. M. Weiss, "*Toxoplasma gondii*: from animals to humans," *International Journal for Parasitology*, vol. 30, no. 12–13, pp. 1217–1258, 2000.
- [200] A. J. Cook, R. E. Gilbert, W. Buffolano et al., "Sources of toxoplasma infection in pregnant women: European multicentre case-control study. European Research Network on Congenital Toxoplasmosis," *BMJ*, vol. 321, no. 7254, pp. 142–147, 2000.
- [201] E. B. Madsen, "Standardiseret behandling [standardized treatment]," *Ugeskrift for Laeger*, vol. 152, no. 37, pp. 2659–2660, 1990.
- [202] K. Sugden, T. E. Moffitt, L. Pinto, R. Poulton, B. S. Williams, and A. Caspi, "Is *Toxoplasma gondii* infection related to brain and behavior impairments in humans? Evidence from a population-representative birth cohort," *PLoS One*, vol. 11, no. 2, article e0148435, 2016.
- [203] C. Alvarado-Esquivel, E. M. Méndez-Hernández, J. M. Salas-Pacheco et al., "Toxoplasma gondii exposure and Parkinson's disease: a case-control study," *BMJ Open*, vol. 7, no. 2, article e013019, 2017.
- [204] C. Alvarado-Esquivel, O.-P. Alanis-Quiñones, M.-Á. Arreola-Valenzuela et al., "Seroepidemiology of *Toxoplasma gondii* infection in psychiatric inpatients in a northern Mexican city," *BMC Infectious Diseases*, vol. 6, no. 1, p. 178, 2006.
- [205] H.-L. Wang, G. H. Wang, Q. Y. Li, C. Shu, M. S. Jiang, and Y. Guo, "Prevalence of *Toxoplasma* infection in first-episode schizophrenia and comparison between *Toxoplasma*-seropositive and *Toxoplasma*-seronegative schizophrenia," *Acta Psychiatrica Scandinavica*, vol. 114, no. 1, pp. 40–48, 2006.